Essentiale Forte N

Essentiale Forte N is a widely recognized hepatoprotective medication designed to support liver function. Based on the barcode 3664798042016 and the labeling indicating Opella Healthcare France SAS, this product is part of the consumer healthcare portfolio originally managed by Sanofi. The brand has a deep history in European medicine, specifically targeting liver cell regeneration through essential phospholipids. Currently, manufacturing for this product typically occurs in Germany, serving various international markets including Eastern Europe and France.

The brand is part of Opella, which is the standalone consumer healthcare division of the French pharmaceutical giant Sanofi. In late 2024 and moving into 2025, Sanofi entered into exclusive negotiations with CD&R (Clayton, Dubilier & Rice) for the sale of a controlling stake in Opella, signifying a major shift in ultimate ownership towards a private equity structure while maintaining a significant French presence and Sanofi's minority interest.